Financing translation: Analysis of the NCATS rare-diseases portfolio-Reference-Cited by-同舟云学术

Financing translation: Analysis of the NCATS rare-diseases portfolio

Published:2015-02-25 Issue:276 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Fagnan David E.¹²,Yang N. Nora³,McKew John C.³,Lo Andrew W.¹²⁴⁵

Affiliation:

1. Operations Research Center, Massachusetts Institute of Technology (MIT), Cambridge, MA 02142, USA.

2. Sloan School of Management and Laboratory for Financial Engineering, MIT, Cambridge, MA 02142, USA.

3. National Center for Advancing Translational Sciences, U.S. National Institutes of Health, Rockville, MD 20850, USA.

4. Computer Science and Artificial Intelligence Laboratory and Department of Electrical Engineering and Computer Science, MIT, Cambridge, MA 02139, USA.

5. AlphaSimplex Group, LLC, Cambridge, MA 02142, USA.

Abstract

Simulations using National Center for Advancing Translational Sciences data show that a portfolio of rare-disease therapeutics can yield attractive financial returns.

Funder

NIH

NCATS

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference12 articles.

1. The Global Genes Project “The Global Genes Project” (2014); https://globalgenes.org/rare-diseases-facts-statistics.

2. National Organization of Rare Diseases 4 January 2013; www.rarediseases.org/news-events/news/30-years-oda.

3. FDA Search orphan drug designations and approvals; www.accessdata.fda.gov/scripts/opdlisting/oopd.

4. Financing drug discovery for orphan diseases

5. Scientific Management Review Board Report on Translational Medicine and Therapeutics (NIH Bethesda 2010).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences;Orphanet Journal of Rare Diseases;2023-09-12

2. Who counts as an inventor? Seniority and gender in 430,000 biomedical inventor–researcher teams;Nature Biotechnology;2023-05

3. Financial intermediation and the funding of biomedical innovation: A review;Journal of Financial Intermediation;2023-04

4. Making orphan drugs and services available and accessible for people who live with rare diseases: what has been done? a systematic scoping review;Expert Opinion on Orphan Drugs;2022-12-02

5. Financing Biomedical Innovation;Annual Review of Financial Economics;2022-11-01